Trazodone and doxepin are both antidepressants widely prescribed for insomnia, but they reach their sedative effects through different brain pathways and carry different guideline support. The only published head-to-head comparison found no meaningful difference in treatment failure between the two, with roughly a third of trazodone patients and about two-fifths of doxepin patients needing a change in therapy. Yet major sleep-medicine guidelines draw a sharper line, weakly recommending doxepin while weakly recommending against trazodone for chronic insomnia. That split between real-world outcomes and guideline positions is what makes this comparison worth unpacking.
How They Work Differently
Trazodone and doxepin both cause drowsiness, but through distinct pharmacological routes. At the low doses typically used for sleep, trazodone acts primarily by blocking serotonin 2A receptors and alpha-1 adrenergic receptors, with partial activity at serotonin 1A receptors. Those are its strongest binding targets, and at doses around 50 mg they are the main ones it engages. The serotonin-blocking and alpha-blocking combination is what drives the sedation most people feel. At higher antidepressant doses (around 300 mg), trazodone recruits additional actions, including serotonin reuptake inhibition and blockade of histamine H1 receptors, which adds to its mood-lifting and sedative properties.1PubMed Central. Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations
Doxepin takes a fundamentally different path. It is a tricyclic antidepressant, but at the very low doses used for insomnia (1 to 6 mg), it behaves almost exclusively as a histamine H1 blocker. Its affinity for the H1 receptor is exceptionally strong, in the subnanomolar range, meaning it latches onto those receptors at concentrations far below what is needed to affect other receptor systems.2PubMed. Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin At higher antidepressant doses (75 to 150 mg), doxepin engages norepinephrine and serotonin reuptake inhibition along with anticholinergic effects, but those properties are essentially absent at the insomnia doses. This selectivity is the central reason low-dose doxepin was approved specifically for insomnia by the FDA, while trazodone remains an off-label choice for sleep.
The practical consequence is that these drugs feel different in the body. Trazodone’s alpha-1 blockade can lower blood pressure noticeably, which contributes to dizziness on standing up. Doxepin at sleep doses avoids that particular issue because it is not meaningfully blocking adrenergic receptors. On the other hand, both drugs promote drowsiness through overlapping downstream effects on the histamine system, which is why either one can help a person fall or stay asleep.
What the Head-to-Head Evidence Shows
Direct comparisons between trazodone and doxepin are surprisingly thin for two drugs so commonly prescribed for the same problem. The most relevant published study is a retrospective look at psychiatric inpatients who received either trazodone 50 mg or doxepin 25 mg as a sleep aid. Treatment failure, defined as needing a medication change due to poor efficacy or side effects, occurred in about 35% of trazodone patients and 41% of doxepin patients. That difference was not statistically significant.3PubMed Central. Trazodone versus doxepin as a pharmacologic sleep aid in psychiatric inpatients: A retrospective cohort study
Among patients whose initial trazodone failed, the study also compared stepping up to trazodone 100 mg versus switching to doxepin 25 mg. Again, there was no significant difference in how well either option worked or how well it was tolerated. Most treatment failures in both groups were driven by the medication simply not being effective enough, not by intolerable side effects. Only a handful of patients in either group stopped because of adverse events: one trazodone patient and two doxepin patients reported next-day grogginess bad enough to warrant a switch, and one doxepin patient discontinued for constipation.4PubMed Central. Trazodone versus doxepin as a pharmacologic sleep aid in psychiatric inpatients: A retrospective cohort study
This is helpful but limited. It was retrospective, conducted in a psychiatric hospital setting, and involved 122 patients total. These were not otherwise-healthy insomnia patients; they were people admitted for mental health conditions who also needed help sleeping. The doses used (trazodone 50 mg, doxepin 25 mg) are the ranges typical for off-label sedation rather than the ultra-low FDA-approved doxepin doses of 3 to 6 mg. No large randomized head-to-head trial comparing these two drugs in a general insomnia population has been published, which is a meaningful gap given how often both are prescribed.
What Sleep Guidelines Say
The American Academy of Sleep Medicine’s clinical practice guideline for chronic insomnia treatment draws a clear distinction between these two medications. It weakly suggests that clinicians use doxepin for sleep maintenance insomnia, while weakly suggesting against the use of trazodone for either sleep onset or sleep maintenance insomnia.5PubMed Central. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline Both recommendations are classified as “weak,” meaning the evidence behind them is not overwhelming and clinician judgment plays a large role.
The reasoning behind the split is straightforward: low-dose doxepin has been evaluated in multiple randomized, double-blind, placebo-controlled trials designed specifically for insomnia, which led to FDA approval for that indication.6PubMed Central. Therapeutic rationale for low dose doxepin in insomnia patients Trazodone, despite being one of the most commonly prescribed medications for insomnia in the United States, has a thinner evidence base of formal insomnia trials. A systematic review found that evidence for trazodone’s effectiveness has been demonstrated across primary insomnia and insomnia linked to depression, dementia, and other conditions, but the overall quality of the trial data was not as robust as what exists for doxepin.7PubMed Central. Trazodone for Insomnia: A Systematic Review
This creates an odd situation where trazodone is used far more often than doxepin in clinical practice, yet the guideline it appears in gives it less favorable treatment. One critical appraisal of the evidence noted that some recent clinical guidelines do not recommend trazodone as a first-line insomnia medication, but the authors argued that the evidence deserves closer scrutiny rather than outright dismissal.8PubMed Central. Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal The disconnect between prescribing habits and guideline language reflects a broader tension in sleep medicine: clinicians have decades of experience using trazodone for insomnia, and many find it effective, but the formal evidence that guideline panels evaluate has not caught up to that clinical familiarity.
Side Effects at Sleep Doses
At the doses used for insomnia, both drugs are generally well tolerated, but their side-effect profiles differ in ways that matter for certain patients. Trazodone’s most commonly reported side effect is drowsiness, which is technically the intended effect at bedtime but can carry over into the morning. Beyond sedation, trazodone can cause orthostatic hypotension, meaning a drop in blood pressure when you stand up. In elderly patients, trazodone showed notably lower rates of anticholinergic and cardiovascular effects compared to older tricyclic antidepressants, but orthostatic hypotension, heart rhythm irregularities, and priapism remain concerns that need monitoring.9PubMed. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders
Priapism, a prolonged and painful erection unrelated to sexual arousal, is rare but is a distinctive and serious risk associated with trazodone. It occurs most often in men and can require emergency medical treatment. There is no comparable risk with doxepin. This is one of the clearest differentiators between the two medications from a safety perspective.
Low-dose doxepin, by contrast, largely avoids the traditional tricyclic side-effect package. At 3 to 6 mg, the anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision) that plague doxepin at antidepressant doses are minimal or absent. Clinical trials in both adults and elderly patients found the drug well tolerated at those low doses, with a side-effect profile not dramatically different from placebo.10PubMed Central. Therapeutic rationale for low dose doxepin in insomnia patients The catch is that many prescribers use doxepin at higher doses (10 to 25 mg or more) for insomnia, especially when using generic formulations rather than the branded low-dose product, and at those doses the anticholinergic effects start to appear. This means the clean safety profile described in the clinical trials does not necessarily translate to all real-world prescribing.
Effects on Sleep Architecture
Not all sleep aids improve sleep in the same way. Some knock you out but suppress the deep or REM stages that are most restorative. How trazodone and doxepin handle sleep architecture is relevant to understanding their quality, not just their quantity, of sleep improvement.
A systematic review and meta-analysis of trazodone’s effects on polysomnography measures found that trazodone significantly increased total sleep time by roughly 40 minutes compared to controls. It also significantly increased the amount of deep sleep (stage N3). Trazodone did not have an obvious effect on REM sleep, lighter sleep stages, or overall sleep efficiency in the pooled analysis.11PubMed Central. Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations The increase in deep sleep is considered a favorable property because many insomnia patients specifically lack this slow-wave stage, and some other sedatives (like benzodiazepines) tend to suppress it.
Doxepin at the 6 mg dose showed strong improvements in a transient insomnia model: it reduced the time to fall asleep by about 13 minutes versus placebo, cut time awake after falling asleep by 39 minutes, and increased total sleep time by 51 minutes. It improved sleep efficiency across all quarters of the night, meaning the benefit was not concentrated just at the beginning or end of the sleep period. The study also noted only minor alterations to sleep stages, with no consistent evidence of next-day grogginess.12PubMed. Efficacy and safety of doxepin 6 mg in a model of transient insomnia
Both drugs, then, appear to add meaningful sleep time without major disruptions to sleep architecture. Trazodone has a notable edge in boosting deep sleep specifically. Doxepin’s consistent benefit across all night quarters makes it particularly useful for people whose main problem is waking up too early or too often, rather than trouble falling asleep initially.
Dose Makes All the Difference
One of the biggest sources of confusion when comparing these two drugs is that both have very different effects depending on the dose. This is not a subtle pharmacological footnote; it fundamentally changes what the drug is doing in your brain.
For trazodone, low doses around 50 mg primarily block serotonin 2A and alpha-1 adrenergic receptors, which accounts for the sedative and sleep-promoting effects. A study modeling brain receptor occupancy estimated that these receptors are occupied at reasonable levels (above 59%) at this dose.13PubMed Central. Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations At antidepressant doses of 150 to 300 mg, trazodone additionally blocks the serotonin transporter and engages histamine, serotonin 2C, and serotonin 7 receptors. In other words, the 50 mg sleep dose and the 300 mg antidepressant dose are pharmacologically different drugs in practical terms. Research has indicated that 50 mg daily should be sufficient to block the receptors responsible for the sleep-promoting effect and may also provide some protection against neuroinflammation, which could be relevant for patients with dementia.14PubMed. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets
Doxepin shows an even more dramatic dose-dependent shift. At 1 to 6 mg, it is essentially a pure histamine blocker. At 25 to 50 mg, it starts acting on norepinephrine and serotonin systems. At 75 to 150 mg (antidepressant range), it is a full tricyclic with all the associated anticholinergic and cardiovascular baggage. The FDA-approved insomnia product (Silenor) contains just 3 or 6 mg, but in practice many providers prescribe generic doxepin capsules at 10, 25, or even 50 mg for sleep. Those higher doses deliver a meaningfully different pharmacological experience, with more side effects and less selectivity, than the rigorously studied low-dose formulation.
A trial of doxepin at 1 mg, 3 mg, and 6 mg found that all three doses improved total sleep time and sleep efficiency compared to placebo, while the 3 mg and 6 mg doses also improved the primary endpoint of wake time during the night.15PubMed Central. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia This matters because it shows that you do not need to push the dose high to get a real sleep benefit from doxepin. The cleaner side-effect profile at low doses is part of why guideline panels favored it.
Drug Interactions and Metabolism
How your body breaks down these drugs affects how they interact with other medications, which can be a practical deciding factor. Trazodone is primarily metabolized by the liver enzyme CYP3A4, which is responsible for processing a huge proportion of commonly used medications. CYP2D6 and CYP2C19 also contribute to forming other metabolites.16PubMed Central. Characterization of trazodone metabolic pathways and species-specific profiles This means that drugs which inhibit CYP3A4 (certain antifungals, some antibiotics, grapefruit juice in large amounts) can raise trazodone levels in the blood. Conversely, strong CYP3A4 inducers (like certain anti-seizure medications) can reduce its effectiveness.
Doxepin is also metabolized by CYP enzymes, primarily CYP2D6 and CYP2C19. People who are genetically slow metabolizers of CYP2D6, a variation found in roughly 5 to 10% of people of European descent, may accumulate higher doxepin levels than expected. This genetic variability is less of a concern at the ultra-low insomnia doses, where total drug exposure is small, but becomes clinically relevant if doxepin is used at higher doses.
Both drugs can interact with other serotonergic medications, raising the theoretical risk of serotonin syndrome when combined with SSRIs, SNRIs, or other serotonin-active drugs. In practice, trazodone at sleep doses and low-dose doxepin are commonly co-prescribed alongside antidepressants, but this combination warrants awareness. Trazodone generates an active metabolite called mCPP (meta-chlorophenylpiperazine), which has its own pharmacological activity and can cause anxiety or headache in some people, particularly if CYP3A4 metabolism is altered.
Choosing Between Them in Practice
If guideline support and formal trial evidence matter most to you or your prescriber, doxepin at the FDA-approved low doses (3 to 6 mg) has the edge. It is the only drug in this pairing with a formal insomnia indication, backed by randomized controlled trials in both younger and older adults. Its side-effect profile at those doses is clean, and it avoids the orthostatic hypotension and priapism risks that come with trazodone.
Trazodone, however, has practical advantages that explain its dominance in prescribing. Generic trazodone is inexpensive and widely available. It has a long track record of clinical use. Some prescribers prefer it for patients who have both insomnia and anxiety or depression, since even at low doses it engages serotonin receptors in ways that may offer some mood benefit. Its ability to boost deep sleep is appealing for people who feel their sleep is shallow and unrefreshing. And the fact that it is not a controlled substance, unlike benzodiazepine or Z-drug sleep aids, makes it easier to prescribe and refill.
Low-dose branded doxepin (Silenor) can be expensive without insurance, which has pushed many prescribers toward using generic doxepin capsules at slightly higher doses. That workaround trades some of the clean pharmacological selectivity for cost savings, and the side-effect profile at 10 or 25 mg is not the same as at 3 or 6 mg. This practical reality muddies the tidy comparison that clinical trials established.
When One Might Be Preferred Over the Other
Certain patient characteristics push the balance in one direction. For men, the priapism risk with trazodone, while uncommon, is a reason some prescribers default to doxepin. For patients already taking medications that strongly inhibit CYP3A4, doxepin may be a simpler choice to avoid trazodone drug interactions. For older adults, both drugs carry fall risk from sedation, but trazodone’s additional blood-pressure-lowering effect may make orthostatic hypotension a bigger concern in a population already prone to dizziness and unsteady balance.
For patients whose primary complaint is waking up too early in the morning and being unable to fall back asleep, doxepin’s sustained benefit across all quarters of the night is a good match.17PubMed. Efficacy and safety of doxepin 6 mg in a model of transient insomnia For patients who report sleeping lightly without enough restorative deep sleep, trazodone’s demonstrated boost to slow-wave sleep could be the more appealing option. For patients with comorbid depression, the choice may hinge on what antidepressant they are already taking and whether adding either drug creates interaction concerns or therapeutic redundancy.
For patients with dementia-related insomnia, trazodone has some specific research attention. Modeling studies have suggested that the receptor occupancy profile at low doses could provide protective effects against neuroinflammation and neurodegeneration in addition to the sleep benefit.18PubMed. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets This is preliminary and not confirmed in large clinical trials, but it has made trazodone a common choice in dementia care settings.
The Evidence Gap That Still Exists
The biggest frustration with this comparison is how little direct evidence we have. The retrospective inpatient study of 122 psychiatric patients is, as of now, the only published head-to-head comparison. No large randomized controlled trial has pitted trazodone against doxepin in a general insomnia population using standardized sleep measurements and modern trial design. This means clinicians are largely extrapolating from separate bodies of evidence for each drug and making educated guesses about how the two would compare directly.
Trazodone’s evidence base for insomnia is broad but shallow. It has been studied across multiple populations, including people with primary insomnia, depression-related insomnia, and dementia-related sleep disturbance, but many of those studies were small, open-label, or used older trial designs.19PubMed Central. Trazodone for Insomnia: A Systematic Review Doxepin’s insomnia evidence is narrower but deeper: fewer populations studied, but with the kind of large, rigorous placebo-controlled trials that regulatory agencies and guideline panels weigh heavily. Whether breadth or depth of evidence is more reassuring depends partly on your perspective and partly on which patient population you belong to.
The field could use a pragmatic trial comparing real-world outcomes for both drugs across diverse patient groups, including older adults, people with psychiatric comorbidities, and those with both sleep onset and sleep maintenance problems. Until that trial materializes, the honest answer is that both drugs help many people sleep, both fail for a meaningful minority, and the choice between them depends more on individual patient factors and prescriber experience than on any definitive evidence that one is superior.